Plné znění - 47/2014 Sb. m. s.

Sdělení o přijetí nového znění Přílohy I (Seznam zakázaných látek a metod - Mezinárodní standard) Mezinárodní úmluvy proti dopingu ve sportu

47/2014 Sb. m. s.

Sdělení

INFORMACE

47

XXXXXXX

Xxxxxxxxxxxx xxxxxxxxxxxx xxxx,

xxxxxx xx xxxx x xxxxxxxx sdělení Xxxxxxxxxxxx xxxxxxxxxxxx xxxx x. 58/2007 Xx. m. x. x x. 46/2008 Xx. m. x. a nahrazuje xxxxxxx Xxxxxxxxxxxx xxxxxxxxxxxx xxxx x. 98/2013 Xx. x. x. x Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx xxxxxx

Xxxxxxxxxxxx xxxxxxxxxxxx xxxx xxxxxxx, že xxx 11. listopadu 2013 xxxx generální ředitelkou XXXXXX oznámeno xxxxxxxxx xxxxxx xxxxx Xxxxxxx X - Xxxxxxx xxxxxxxxxx xxxxx a xxxxx - Xxxxxxxxxxx xxxxxxxx Mezinárodní xxxxxx xxxxx xxxxxxx xx xxxxxx.¹⁾

X xxxxx zněním Xxxxxxx I xxxxxxxx xxxxxxx Xxxxxxxxx Xxxxx xxxxxxxxx x xxxxxxxxx xxxxxxxxx xxxxxxxx listinu x přijetí změny Xxxxxxx I Xxxxxx xxxxxxxxxx.

Xxxx xxxxx Přílohy X vstoupilo x xxxxxxxx x souladu x článkem 34 xxxx. 3 Úmluvy xxx 1. ledna 2014 x xxxxx xxxx vstoupilo v xxxxxxxx x xxx Xxxxxx xxxxxxxxx. Xxxx xxxxxx nového xxxxx Xxxxxxx X x xxxxxxxx přestalo platit xxxxx Xxxxxxx I Xxxxxxxxxxx úmluvy xxxxx xxxxxxx ve sportu xxxxxx xx 1. xxxxx 2013 a xxxxxxxxx xxx č. 98/2013 Sb. m. s.

Xxxxxxxx xxxxx Přílohy I x xxxx xxxxxxx xx českého xxxxxx xx vyhlašují xxxxxxxx.

¹⁾ Xxxxxxxxxxx úmluva proti xxxxxxx xx xxxxxx xxxxxxx xxx 19. xxxxx 2005 x Xxxxxx xxxx xxxxxxxxx xxx č. 58/2007 Sb. m. s. a č. 46/2008 Sb. m. s.

XXXXXXXXXXX XXXXXX PROTI XXXXXXX XX XXXXXX
Xxxxxxx X - Seznam xxxxxxxxxx látek a xxxxx - Xxxxxxxxxxx xxxxxxxx
Xxxxx, 1. ledna 2014

XXXXXX XXXXXXXXXX XXXXX X XXXXX DOPINGU XXX XXX 2014

XXXXXXX XXXXXXXXXXXXX XXXXX

Xxxxxx od 1. xxxxx 2014

Podle xxxxxx 4.2.2 Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxx všechny Xxxxxxxx látky budou xxxxxxxxxx xx "Xxxxxxxxxx xxxxx" xxxxx látek xx xxxxxx X1, X2, X4.4, S4.5 x X6(x) x Xxxxxxxxxx xxxxx X1, X2 a M3.

LÁTKY X METODY ZAKÁZANÉ XXXXX (XXX XXXXXXX I XXXX XXXXXX)

XXXXXXXX LÁTKY

S0. XXXXXXXXXXX XXXXX

Xxxxxxxxx xxxxxxxxxxxxx xxxxx, která xxxx xxxxxxxx x xxxxxxxxxxxxx xxxxxxx Xxxxxxx a xxxx aktuálně schválena xxx humánní xxxxxxxxxxxx xxxxxxx jakýmkoliv xxxxxxx xxxxxxxxxxxxx xxxxxxxxxx úřadem (xxxx. léčiva x xxxxxxxxxxxx nebo xxxxxxxxx xxxxxx xxxxxxx nebo xx xxxxxxxx xxxxxxxxxx, xxxxxxxxxx xxxxx, xxxxx xxxxxxxxx pouze xxx xxxxxxxxxxx xxxxxxx), xx xxxxxxxx stále.

S1. XXXXXXXXXX XXXXX

Xxxxxxxxxx xxxxx jsou xxxxxxxx.

1. XXXXXXXXXX XXXXXXXXXX XXXXXXXX (AAS):

(a) Xxxxxxxx* XXX, xxxxxxxxxx:

1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3x,17β-xxxx); 1-xxxxxxxxxxxxx (5α-androst-1-en-3,17-dion); xxxxxxxxx (xxxx-4-xx-3β,17β-xxxx); xxxxxxxxxx; xxxxxxxx; xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx); xxxxxxx ([1,2]xxxxxx[4',5':2,3]xxxxxx-4-xx-20-xx-17α-xx); dehydrochlormethyltestosteron (4-xxxxxx-17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxxxxxxxxxxxxxxxx (17α-methyl-5α-androst-2-en-17β-ol); xxxxxxxxxxx; xxxxxxxxxxxxx (19-nor-pregna-4-en-17α-ol); xxxxxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxx (17α-xxxxxx[1,2,5]xxxxxxxxxx[3',4':2,3]-5α-xxxxxxxxx-17β-xx); xxxxxxxxx; 4-xxxxxxxxxxxxxxxxxx (4,17β-xxxxxxxxxxxxxxxx-4-xx-3-xx); xxxxxxxxxx; klostebol; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx (17β-hydroxy-17α-methylandrosta-1,4-dien-3-on); xxxxxxxxx; methandriol; xxxxxxxxxx (17β-xxxxxxx-2α,17α-xxxxxxxx-5α-xxxxxxxxx-3-xx); xxxxxxxxxxxxxx (17β-hydroxy-17α-methylestra-4,9-dien-3-on); xxxxxx-1-xxxxxxxxxxx (17β-hydroxy-17α-methyl-5α-androst-1-en-3-on); xxxxxxxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx); methyltestosteron; xxxxxxxxxx (xxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9,11-xxxxx-3-xx); xxxxxxxxx; xxxxxxxxx; 19-xxxxxxxxxxxxxxxx (estr-4-en-3,17-dion); xxxxxxxxxx; xxxxxxxxxxxxxx; xxxxxxxxxxxx; xxxxxxxx; xxxxxxxxxx; oxymesteron; xxxxxxxxxx; prostanozol (17β-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1'X-xxxxxxxx[3,4,:2,3]-5α-xxxxxxxxxx); xxxxxxxxx; xxxxxxxxxx; stenbolon; 1-xxxxxxxxxxx (17β-hydroxy-5α-androst-1-en-3-on); tetrahydrogestrinon (17-xxxxxxx-18α-xxxx-19-xxx-17α-xxxxxx-4,9,11-xxxxx-3-xx); xxxxxxxxx (17β-xxxxxxxxxx-4,9,11-xxxxx-3-xx) x xxxxx xxxxx x podobnou xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.

(x) Xxxxxxxxx** XXX, xxxxx jsou xxxxxx xxxxxxxx:

Xxxxxxxxxxxxx (xxxxxxx-5-xx-3β,17β-xxxx), xxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx), xxxxxxxxxxxxxxxxxx, xxxxxxxxx (dehydroepiandrosteron, XXXX), 3β-xxxxxxxxxxxxx-5-xx-17-xx), testosteron x xxxxxx xxxxxxxxxx x xxxxxxx, ale xx x omezením pouze xx xx:

5α-xxxxxxxxx-3α,17α-xxxx	5-xxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx)
5α-xxxxxxxxx-3α,17β-xxxx	xxx-xxxxxxxxxxxxxxxxxx
5α-xxxxxxxxx-3β,17α-xxxx	xxxxxxxxxxxxxx
5α-xxxxxxxxx-3β,17β-xxxx	xxxxxxxxxxxxxx
xxxxxxx-4-xx-3α,17α-xxxx	3α-xxxxxxx-5αxxxxxxxxx-17-xx
xxxxxxx-4-xx-3α,17β-xxxx	3β-xxxxxxx-5αxxxxxxxxx-17-xx
xxxxxxx-5-xx-3β,17α-xxxx	7α-xxxxxxx-XXXX
xxxxxxx-5-xx-3α,17α-xxxx	7β-xxxxxxx-XXXX
xxxxxxx-5-xx-3α,17β-xxxX	7-xxxx-XXXX
xxxxxxx-5-xx-3β,17α-xxxx	19-xxxxxxxxxxxxxx
4-xxxxxxxxxxxxx (xxxxxxx-4-xx-3β,17β-xxxx)	19-xxxxxxxxxxxxxxxxx

Xxx xxxxx xxxxxxx xxxx xxxxx:

* "xxxxxxxx" xx xxxxxxxx x xxxxx, xxxxxx tělo xxxxxxxx přirozeně neprodukuje.

** "xxxxxxxxx " xx xxxxxxxx k xxxxx, xxxxxx xxxx normálně xxxxxxxxx xxxxxxxxx.

2. Xxxxxxx xxxxxxxxxx látky, xxxxxxxxxx:

Xxxxxxxxxxx, xxxxxxxxxx xxxxxxxxxx androgenových xxxxxxxxx (SARM), xxxxxxx, xxxxxxx, xxxxxxxxxx, xxx xx s xxxxxxxx xxxxx xx xx.

X2. XXXXXXXXX XXXXXXX, XXXXXXX XXXXXXX X XXXXXXXX XXXXX

Xxxxxxxxxxx látky x xxxxx xxxxx x xxxxxxxx chemickou xxxxxxxxxx xxxx xxxxxxxxx biologickými xxxxxx xxxx zakázány:

1. Xxxxx xxxxxxxxxxx xxxxxxxxxxx (xxxx. erytropoetin (XXX), xxxxxxxxxxx (xXXX), xxxxxxxxxxxxx xxxxxxx vyvolávajícího faktoru (XXX), methoxypolyethylenglykol-epoetin beta (XXXX), peginesatid /Xxxxxxxx/);

2. Xxxxxxxxxxxxxxxxxx (CG) a Xxxxxxxxxxxx xxxxxx (XX) x xxxxxx uvolňující xxxxxxx x xxxx;

3. Xxxxxxxxxxxxxx a xxxxxx xxxxxxxxxx faktory;

4. Xxxxxxx xxxxxx (GH) a xxxx uvolňující faktory x xxxxxxxx xxxxxxx xxxxxxx faktor-1 (XXX-1).

Xxxxx xxxx xxxx xxxxxxxx xxxxxxxxxxx xxxxxxx xxxxxxx:

Xxxxxxxxxxxxx xxxxxxx faktory (FGFs), xxxxxxxxxxxx xxxxxxx faktor (XXX), xxxxxxxxxx xxxxxxx xxxxxxx (MGF), xxxxxxx xxxxxx xxxxxxxx x xxxxxxxx destiček (XXXX) x vaskulárně-endoteliární xxxxxxx xxxxxx (VEGF), xxxxxx xxxx xxxxxxxxx xxxx xxxxxxx xxxxxxx ovlivňující xxxxxxx xxxx xxxxxxxxx xxxxxxxx xxxxx, xxxxx x xxxxxx, krevní xxxxxxxx, xxxxxxx xxxxxxx, xxxxxxxxxxxxx xxxxxxxx nebo xxxxxxxxxxx xxxx xxxxxxxxx xxxxxx;

x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx účinky.

S3. BETA2- XXXXXXXX

Xxxxxxx beta-2 agonisté, xxxxxx xxxxx případných xxxxxxxxx xxxxxxx (xxxx. x- x x-), xxxx xxxxxxxx kromě xxxxxxxxxxx salbutamolu (xxxxxxxxx 1600 xxxxxxxxxx xx 24 hodin), xxxxxxxxxxxx xxxxxxxxxxx (maximální xxxxxx xxxxx 54 xxxxxxxxxx xx 24 hodin) x xxxxxxxxxxx, xxxxx xxxx xxxxxx v xxxxxxxx v xxxxxxx x doporučeným léčebným xxxxxxx xxxxxxx.

Xxxxxxxxxx xxxxxxxxxxx x moči x xxxxxxxxxxx xxxxx xxx 1000 xx/xx x xxxxxxxxxx xxxxxxxxxxx x xxxx x koncentraci xxxxx než 40 xx/xx nebude považována xx xxxxxxxxx xxxxxxxxxxxx xxxxxxx, ale xxxx xxxxxxxxxx za pozitivní xxxxxxxxxxx xxxxx, xxxxx xxxxxxxxx neprokáže xxxxxxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxx, xx xxxxxxxxxx xxxxxxxx byl xxxxxxxx xxxxxxxx xxxxxxxxxxxx xxxxxxxxx xxxxx xxxxx xxx xxxx xxxxxxx xxxxxxx.

X4. XXXXXXXXX X XXXXXXXXXXX XXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

1. Xxxxxxxxxx aromatáz, xxxxxxxxxx:

Xxxxxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxx-1,4,6-xxxxx-3-17-xxxx (xxxxxxxxxxxxxxxxx), 4-xxxxxxxxx-3,6,17-xxxxx (6-oxo), xxxxxxxxx, xxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxx xx x omezením xxxxx xx xx.

2. Selektivní xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX), xxxxxxxxxx:

Xxxxxxxxx, tamoxifen, xxxxxxxxx, xxx xx x xxxxxxxx xxxxx xx ně.

3. Xxxxxxx xxxxxxxxxxxxxx xxxxx xxxxxxxxxx:

Xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxx, xxx xx s omezením xxxxx xx xx.

4. Xxxxx xxxxxxxxxxxx xxxxxx xxxxxxxxxx včetně xxxxxxxxxx xxxxxxxxxx, xxx ne x xxxxxxxx xxxxx xx xx.

5. Xxxxxxxxxxx xxxxxxxxxx:

x) Insuliny;

b) Xxxxxxxx xxxxx xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxxx /Xxxxxxxxxx Xxxxxxxxxxxx Xxxxxxxxx Xxxxxxxx δ (XXXXδ) xxxxxxxx/ (xxxx. XX 1516) x Xxxxxxxx xxxxxxxxxxxxxxx xxx xxxxxxxxxx XXX v xxxxxxxxxxx x XXXX xxxxx /XXXXδ-XXX-xxxxxxxxx xxxxxxx xxxxxx (XXXX) xxxx xxxxxxxx/ (např. AICAR)

S5. XXXXXXXXX A OSTATNÍ XXXXXXXXX XXXXX

Xxxxxxxxx xxxxx xxxx xxxxxxxx. Zahrnují:

Diuretika, xxxxxxxxxxxx, xxxxxxxxxxxxxxx (např. xxxxxxxx, xxxxxxxxxx xxxxxx xxxxxxxx, xxxxxxxx, xxxxxxxxxxxxxxxxxx x xxxxxxxxx), xxxxxxxxxx x další xxxxx x xxxxxxxxx xxxxxxxxxxxx xxxxxx. Xxxxxxx xxxxxx xxxxxxxxxxxx xxx zubní xxxxxxxx xxxx xxxxxxxx.

Xxxxxxxxx xxxxxxxx:

Xxxxxxxxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxx, xxxxxxxx, xxxxxxxx xxxxxxxxxx, xxxxxxxxx, spironolakton, xxxxxxxx (xxxx. bendroflumethiazid, hydrochlorothiazid, xxxxxxxxxxxxx), xxxxxxxxxx, vaptany (xxxx. tolvaptan) x xxxxx xxxxx s xxxxxxxx chemickou xxxxxxxxxx xxxx xxxxxxxxx biologickými xxxxxx (kromě xxxxxxxxxxxx, xxxxxxxxx x xxxxxxxxx xxxxxx xxxxxxxxxxx a xxxxxxxxxxxx, xxxxx xxxxxx xxxxxxxx).

Xxx xxxxxxx (Xxx Xxxxxxx, xxxxxxxx Xxxx Xxxxxx) xxxxxxxxxxx xxxxxxxx xxxxx xx xxxxxxxxxx xxxxxxxx xxxxxxx (xx. xxxxxxxxxx, xxxxxxxxxx, katin, xxxxxxx, metylefedrin x xxxxxxxxxxxxx) xx spojení x diuretikem xxxx xxxxx maskovací látkou xx vyžadováno xxxxxxx xxxxxxxxxx Terapeutické xxxxxxx xx xxxx xxxxx xxxxx x té, xxxxx již xxxx xxxxxxx na xxxxxxxxxx xxxx jinou xxxxxxxxx xxxxx.

XXXXXXXX METODY

M1. XXXXXXXXXX X XXXX X XXXXXXXX XXXXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

1. Xxxxxx nebo xxxxxxxxxxxxx jakéhokoliv xxxxxxxx xxxxxxxxx, xxxxxxxx (homologní) xxxx xxxxxxxxxxx xxxx xxxx červených xxxxxxx x xxx xxxxxxxxx xxxxxxxx xxxxxxxxxxx původu xx xxxxxxxxx systému.

2. Xxxxx zvyšování xxxxxxxx, xxxxxxx xxxx xxxxxxx xxxxxxx, zahrnující xxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx (xxxx. xxxxxx náhražky založené xx hemoglobinu, xxxxxxxxxxxxxxxxxx xxxxxxxxxxx), perfluorochemikálie a xxxxxxxxxxx (RSR13), xxx xx x xxxxxxxx xxxxx na ně. Xxxxxxxxxxxx kyslíkem zakázána xxxx.

3. Xxxxxxxxx xxxxx xxxxxxxxxxxxxxx xxxxxxxxxx x xxxx xxxx x xxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx xxxx chemickými xxxxxxx.

X2. XXXXXXXX A XXXXXXXXX XXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

1. Xxxxxxxxx, nebo xxxxx x xxxxxx, xx xxxxxx porušit integritu x xxxxxxxx Xxxxxx xxxxxxxxxx xxx Xxxxxxxxx xxxxxxxx. Xx xxxxxxxx xxxxxx a/nebo xxxxxx (xxxx. xxxxxxxxxx) xxxx, xxx xx x xxxxxxxx xxxxx xx xx.

2. Xxxxxxxxxx xxxxxx x/xxxx injekce více xxx 50 xx xx 6 hodin xxxxx xxxxxx legitimně xxxxxxxxx v xxxxxxx xxxxxxxxxxxx xxxxxxx xxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxx.

X3. XXXXXX XXXXXX

X xxxxxx xxxxxxxxxx ke xxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxx xxxxxxxxxxx:

1. Xxxxxxxx xxxxxxxx nukleových xxxxxxx xxxx jejich analogů;

2. Xxxxxxx normálních xxxx xxxxxxxxx xxxxxxxxxxxxxx buněk.

LÁTKY X METODY XXXXXXXX XXX SOUTĚŽI

Kromě kategorií X0 až S5 x X1 xx X3 xxxxxxxxx xxxx xxxx Xxx Soutěži xxxxxxxx x xxxxxxxxxxx xxxxxxx:

XXXXXXXX LÁTKY

S6. XXXXXXXXXXX

Xxxxxxx xxxxxxxxxxx xxxxxx xxxxx xxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxx (xxxx. x- x x-) xxxx xxxxxxxx, x xxxxxxxx xxxxxxxx imidazoiu x xxxxxxx xxxxxx místního xxxxxxx x xxxxxxxxxxx xxxxxxxxxx xx Monitorovacího xxxxxxxx xxx rok 2014*.

Xxxxxxxxxxx zahrnují:

(a) Nespecifická xxxxxxxxxxx:

Xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, amifenazol, benfluorex, xxxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, fenproporex, xxxxxxxxx, xxxxxxxxxxxx /4-xxxxxxxxxxxxxx (xxxxxxxx)/, xxxxxxxxxx, xxxxxxxxxxx, kokain, xxxxxxxxxxx, xxxxxxxxxx, mefenorex, xxxxxxxxxxx, metamfetamin (d-), xxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxx, x-xxxxxxxxxxxxxxx, prenylamin, prolintan.

Stimulancium, xxxxx xxxx xxxxxxxx xxxxxxx v tomto xxxxxxxx, xx Xxxxxxxxxxx xxxxxx.

(x) Xxxxxxxxxx xxxxxxxxxxx (xxxxxxxx):

Xxxxxxxxx (xxxxxxxxx)****, xxxxxxxxxxx, xxxxxxxxxxxxxxxxx, efedrin***, xxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, fenprometamin, xxxxxxxxxx, xxxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxxx), xxxxxxxxxxxx, xxxxx**, xxxxxxx x xxxx xxxxxxx (xxxx. mefedron, methedron, xxxx-xxxxxxxxxxxxxxxxxxxxx), xxxxxxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxx***, metylendioxymetamfetamin, metylfenidát, xxxxxxxxxxxxxx (dimetylpentylamin), xxxxxxxxx, xxxxxxxxxxx, oktopamin, xxxxxxxxx (xxxxxxxxxxxxx), xxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxxx, pseudoefedrin*****, selegilin, xxxxxxxxxx, strychnin, xxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx), xxxxxxxxxxxx, tuaminoheptan x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx xxxxxx.

* Následující xxxxx zahrnuté xx Xxxxxxxxxxxxxx programu 2014 (xxxxxxxxx, xxxxxxxxxx, fenylpropanolamin, xxxxxx, xxxxxxx, xxxxxxxxx, xxxxxxxx) xxxxxx xxxxxxxxxx xx Xxxxxxxx xxxxx.

** Xxxxx je zakázaný xxxxx xxx xxxxxxxxxxx xxxxx xxx 5 xxxxxxxxxx x 1 xx moči.

*** Xxxxxxx x methylefedrin xxxx xxxxxxxx xxx xxxxxxxxxxx xxxxx xxx 10 xxxxxxxxxx x 1 xx moči.

**** Xxxxxxx xxxxxx adrenalinu (epinefrinu) (xxxx. xxxxx, xxxx xxxxxxxx) xxxx xxxx xxxxxx společně x xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxx.

***** Xxxxxxxxxxxxx xx xxxxxxx, xxxxx xxxx xxxxxxxxxxx x xxxx xx vyšší xxx 150 xxxxxxxxxx na xxxxxxxx.

X7. XXXXXXXXX

Xxxxxxxx je xxxxxxxxxxx:

Xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxx(xxxxxx), xxxxxxxx x xxxx xxxxxxxx, hydromorfon, xxxxxxx, xxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxx.

X8. XXXXXXXXXXX

Xxxxxxxx (xxxx. xxxxx, xxxxxx x xxxxxxxxx) xxxx xxxxxxxxxx xxxxx9-xxxxxxxxxxxxxxxxxxx (XXX) x kanabimimetika (např. "Xxxxx", XXX018, XXX073 x XX-210) xxxx xxxxxxxx.

X9. XXXXXXXXXXXXXXXXXXXX

Xxxxxxx xxxxxxxxxxxxxxxxxxxx xxxxxxxx xxxxxx, xxxxxxxx, xxxxxxxxxx xxxx nitrosvalovou xxxxxxxx jsou xxxxxxxx.

XXXXX XXXXXXXX X XXXXXXXX XXXXXXXX

X1. XXXXXXX

Xxxxxxx (xxxxxx) xx xxxxxxxx pouze Xxx Soutěži v xxxxxxxxxxxxx xxxxxxxx. Detekce xx xxxx provádět xxxxxxxx zkouškou x/xxxx xxxxxxxx xxxx. Prahová xxxxxxx xxx xxxxxxxx xxxxxxxxxxx xxxxxxxx je xxxxxxxxxxxx xxxxxxxxxxx xxxxxxxx x xxxx 0.10 x/x.

• Xxxxxxxxxxxx xxxxx (XXX)

• Xxxxxx (XXX)

• Xxxxxxx xxxxxx a xxxxxxxxxxxx (XXX)

• Lukostřelba (XX)

• Xxxxxxxxxxx sport (XXX)

• Xxxxx motorismus (XXX)

X2. XXXX-XXXXXXXXX

Xxxxx xxxx xxxxx xxxxxx, xxxx-xxxxxxxxx xxxx xxxxxxxx pouze Xxx Soutěži x xxxxxxxxxxxxx xxxxxxxx.

• Automobilový xxxxx (FIA)

• Xxxxxxxx (xxxxxxx discipliny) (XXXX)

• Xxxx (XXX)

• Xxxxxxxxxxx (XX) (xxxxxxxx xxxx Xxxx soutěž)

• Xxxxxxxx (XXX) - skoky xx lyžích x xxxxxxxxxxx lyžování-skoky x X-xxxxx, x xxxxxxxxx X-xxxxx a "xxx xxx"

• Xxxxxxx (XXXX, XXX) (xxxxxxxx také Xxxx xxxxxx)

• Xxxxx (XXX)

Xxxx-xxxxxxxxx xxxxxxxx následující xxxxx:

Xxxxxxxxxx, alprenolol, xxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, levobunolol, xxxxxxxxxxxx, metoprolol, xxxxxxx, xxxxxxxxxx, pindolol, xxxxxxxxxxx, xxxxxxx, timolol, xxx xx s xxxxxxxx xxxxx xx xx.

Informace

Právní předpis č. 47/2014 Xx. x. x. xxxxx účinnosti xxxx 20.9.2014.

Xxxxxx xxxxxxx x. 47/2014 Xx. x. x. xxx xxxxxx právním xxxxxxxxx č. 19/2017 Sb. m. s. x xxxxxxxxx xx 6.4.2017.

Xxxxx xxxxxxxxxxxx xxxxxxxx norem jiných xxxxxxxx xxxxxxxx x xxxxxxxx xxxx xxxxxxxxxxxxx, xxxxx xx jich xxxxxx xxxxxxxxx xxxxx xxxxx uvedeného xxxxxxxx xxxxxxxx.